Ligand Pharma Reports Signed License Deal Granting Cumulus Oncology Exclusive Global Rights To Develop, Commercialize VER250840 Using Co.'s VDP System; Co. To Receive Upfront License Fee, Eligible For $76M In Milestone Payments
Benzinga Newsdesk